Promoted Content Promoted Content


Find FDA Investigational New Drug (IND) Submissions for Gastroenterology


All Data

Filters Filter refresh
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GT-2108

            Therapeutic Area: Gastroenterology Product Name: GT-2108

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Amplitude Ventures

            Deal Size: $1.2 million Upfront Cash: Undisclosed

            Deal Type: Financing June 30, 2021


            Giiant Pharma already initiated its IND-enabling preclinical program with its lead candidate, GT-2108, for the treatment of moderate-to-severe ulcerative colitis. This additional financing will support the development of GT-2108 up to clinical Phase 1b completion.